Public Employees Retirement System of Ohio Has $2.31 Million Stake in Bausch Health Cos Inc. $BHC

Public Employees Retirement System of Ohio lifted its stake in Bausch Health Cos Inc. (NYSE:BHC) by 112.8% in the first quarter, HoldingsChannel.com reports. The firm owned 429,208 shares of the company’s stock after purchasing an additional 227,466 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Bausch Health Cos were worth $2,312,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Caption Management LLC lifted its stake in shares of Bausch Health Cos by 101.1% during the fourth quarter. Caption Management LLC now owns 4,464 shares of the company’s stock valued at $31,000 after acquiring an additional 405,789 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Bausch Health Cos by 12,589.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock valued at $34,000 after buying an additional 4,910 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in Bausch Health Cos by 6,661.2% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after acquiring an additional 5,329 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Bausch Health Cos by 65.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after purchasing an additional 3,106 shares during the last quarter. Finally, Camelot Portfolios LLC acquired a new position in shares of Bausch Health Cos during the 4th quarter worth about $59,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Insider Activity

In other news, Director Frank D. Lee sold 24,456 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total value of $132,796.08. Following the sale, the director owned 49,339 shares of the company’s stock, valued at $267,910.77. The trade was a 33.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by company insiders.

Bausch Health Cos Stock Up 14.4%

NYSE:BHC opened at $6.90 on Friday. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32. The company has a market cap of $2.58 billion, a PE ratio of -2.33 and a beta of 0.42. Bausch Health Cos Inc. has a 52-week low of $4.33 and a 52-week high of $8.69. The stock has a 50-day simple moving average of $4.99 and a 200 day simple moving average of $5.47.

Bausch Health Cos (NYSE:BHC) last released its earnings results on Wednesday, July 29th. The company reported $1.26 EPS for the quarter, beating the consensus estimate of $0.96 by $0.30. Bausch Health Cos had a negative return on equity of 1,389.97% and a negative net margin of 10.12%.The firm had revenue of $2.83 billion for the quarter, compared to analysts’ expectations of $2.59 billion. On average, sell-side analysts expect that Bausch Health Cos Inc. will post 4.05 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on BHC. Weiss Ratings raised shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday. Wall Street Zen raised shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Royal Bank Of Canada decreased their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a report on Monday, April 27th. Zacks Research cut shares of Bausch Health Cos from a “hold” rating to a “strong sell” rating in a research report on Friday, July 24th. Finally, Jefferies Financial Group raised Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. Five research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $8.00.

Bausch Health Cos Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.